Results 261 to 270 of about 118,516 (288)

Local therapeutic platform prevents postsurgical GBM recurrence by diminishing GICs and reshaping immunosuppressive microenvironment. [PDF]

Nat Commun
Zhu M, Yang M, Li R, Hu X, Chen J, Xu L, Chen S, Li T, Wang J, Zheng B, He H.   +10 more
europepmc   +1 more source

Roxadustat: A catalyst for diabetic wound healing through re-epithelialization and angiogenesis. [PDF]

Cytojournal
Tang D, Lin Q, Xu K, Lu QP.
europepmc   +1 more source

Reply to: "<i>NOTCH1</i>: A Potential New Biomarker in the Era of Immunotherapy?" and "Caution in Interpreting <i>NOTCH1</i> Mutation as a Predictive Biomarker of Tislelizumab Response in Esophageal Squamous Cell Carcinoma". [PDF]

J Clin Oncol
Lu Z, Du W, Jiao X, Wang Y, Zhang Z, Shen L.   +5 more
europepmc   +1 more source

Hif-1 responsive IFFLs to explain specific transcriptional responses to cycling hypoxia in cancers. [PDF]

NPJ Syst Biol Appl
Qiu X, Liu Y, Vera-Licona P, Agmon E, Kshitiz, Suhail Y.   +5 more
europepmc   +1 more source

Caution in Interpreting <i>NOTCH1</i> Mutation as a Predictive Biomarker of Tislelizumab Response in Esophageal Squamous Cell Carcinoma. [PDF]

J Clin Oncol
Lu Z, Yan K, Sheng Y, Rukonge PA, Qin Z, Zhang Z, Yu G.   +6 more
europepmc   +1 more source

<i>NOTCH1</i>: A Potential New Biomarker in the Era of Immunotherapy? [PDF]

J Clin Oncol
Aydemir E, Öksüz NE, Bir Yücel K.
europepmc   +1 more source

Targeting the Notch signaling pathway: molecular mechanisms and therapeutic strategies for cardiac repair after myocardial infarction. [PDF]

Front Cardiovasc Med
Zhang Z, Xie F, Cheng J, Liu X, Wang X, Long J, Feng Q, Yuan D.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Targeting NOTCH1 in Hematopoietic Malignancy

Critical Reviews™ in Oncogenesis, 2011
NOTCH1 is a well-validated target in hematopoietic malignancy, with NOTCH1 activating mutations identified in more than 50% of T-cell acute lymphoblastic leukemias. Moreover, a recent report has identified NOTCH1 activating mutations in 12% of chronic lymphocytic leukemias.
ROTI, GIOVANNI, Stegmaier K.
openaire   +3 more sources

Notch1 promotes cancer spread

Science, 2017
Cancer Mutations that activate Notch have been identified in several cancers. Weiland et al. find that Notch1 signaling within endothelial cells (ECs) promotes the invasion of distant organs by tumors. Abnormally high levels of active Notch1 are found in blood vessels associated with advanced human cancers.
openaire   +2 more sources

p53 regulates thymic Notch1 activation

European Journal of Immunology, 2004
AbstractNotch is crucial for multiple stages of T cell development, including the CD4+CD8+ double positive (DP)/CD8+ single positive (SP) transition, but regulation of Notchactivation is not well understood. p53 regulates Presenilin1 (PS1) expression, and PS1 cleaves Notch, releasing its intracellular domain (NIC), leading to the expression of ...
Amy M, Laws, Barbara A, Osborne
openaire   +2 more sources